Westlake Village BioPartners
VC Fund
Westlake Village, United States
Westlake Village BioPartners is a venture capital firm focused on incubating and building life sciences companies with entrepreneurs that have the potential to bring transformative therapies and technologies to patients. The Westlake model is built on the founding team’s unique experience in successfully identifying and developing breakthroughtherapies and building organizations.
- Total investments:
- 44
- Last investment:
- Lead investor:
- 39%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Westlake Village BioPartners invests in
Stages Westlake Village BioPartners invests in
Countries Westlake Village BioPartners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Sean E. Harper
|
|||
Beth Seidenberg
|
|||
3 more contacts available
Investment Focus
Industry
- Biotechnology 15 (34%)
- Health Care 12 (27%)
- Medical 8 (18%)
- Therapeutics 8 (18%)
- Life Science 5 (11%)
Stage
- Series A 15 (34%)
- Series B 9 (20%)
- Series C 5 (11%)
- Series D 2 (5%)
- Funding Round 2 (5%)
Country
- United States 18 (41%)
- Canada 1 (2%)
- United Kingdom 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Sean E. Harper
Managing Partner
|
Managing Partner | Total investments: 2 | Find email | |
|
Beth Seidenberg
Managing Director
|
Managing Director | Total investments: 35 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Vedana Therapeutics
|
Vedana Therapeutics is a Seattle biotechnology company developing next-generation antibody therapies for migraine prevention. | $46M / Series A / Jun 17, 2026 | |
Oorja Bio
|
Oorja Bio is is a clinical-stage biotechnology company focused on developing therapies for idiopathic pulmonary fibrosis (IPF) and other fibrotic and cardiopulmonary diseases, with a focus on restoring lung tissue function and promoting cellular repair. | $30M / Series A / May 19, 2026 | |
Recludix Pharma
|
Recludix pharma is a developing platform to discover potent and selective inhibitors of challenging protein targets. The platform approach integrates custom generated DNA-encoded libraries, massively parallel determination of structure-activity relationships, and a proprietary screening tool to ensure selectivity. | Jan 12, 2026 | |
Electra Therapeutics
|
Electra Therapeutics is a clinical stage biotechnology company developing therapies for cancer and other immunological diseases. | $183M / Series C / Oct 22, 2025 | |
Star Therapeutics
|
Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients. | $125M / Series D / Sep 30, 2025 | |
AllRock Bio
|
AllRock Bio is a drug developing firm that offers novel therapies to patients suffering hypertension and other fibrotic conditions. | $50M / Series A / Sep 16, 2025 | |
Neuron23
|
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease. | $96.5M / Series D / Jun 24, 2025 | |
Latigo Biotherapeutics
|
Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain. The company utilizes unique, translated insights to provide a differentiated approach to targeting therapeutics across the blood-nerve barrier, enabling patients to get access to a pain management therapy that does not create addiction, dependenceor tolerability. | $150M / Series B / Mar 17, 2025 | |
|
Latigo Biotherapeutics
|
Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain. The company utilizes unique, translated insights to provide a differentiated approach to targeting therapeutics across the blood-nerve barrier, enabling patients to get access to a pain management therapy that does not create addiction, dependenceor tolerability. | $150M / Series B / Mar 17, 2025 | |
Borealis Biosciences
|
Borealis Biosciences is a company in the field of next-generation RNA medicines, specializing in molecular and cellular biology, vivarium space, chemistry, and analytical capabilities. | $30M / Series A / Dec 19, 2024 | |
| See all 44 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Westlake Village BioPartners invest in?
Westlake Village BioPartners invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 44 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Westlake Village BioPartners?
Public channels for Westlake Village BioPartners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Westlake Village BioPartners?
The team at Westlake Village BioPartners includes Sean E. Harper (Managing Partner) and Beth Seidenberg (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
